Well over a century ago, brothers Gustav, Otto and Edward Mallinckrodt founded a chemical company. Today, the company that still bears their name plans a spinoff to try to recreate some of the value that has been lost in the last few years. Mallinckrodt(MNK) today is a second generation spinoff. Grandfather Tyco executed a spinoff of Covidien in… Read More »
Mallinckrodt(MNK) began the week trading at $70 per share. Six months ago, it was above $130. Today, after some comments from Andrew Left of Citron Research, it trades at $62.58, having touched as low as $52.01. The drug company was spun off of Covidien in 2013. Covidien, which had spun out of Tyco(TYC), was acquired in 2014 by… Read More »
Merger Mondays are back. The latest mega deal announced is Medtronic’s (MDT) ~$42.9b takeover of device maker Covidien (COV). The deal price represents a ~30% premium and includes $35.19 of cash and 0.956 Medtronic shares. While Medtronic’s management is out touting the numerous cost savings and synergies gained through the deal, the main motivation behind the deal appears to… Read More »
Nothing like a hurricane to catch up on some old news. At an investor day in early September, Covidien (COV) announced that the spinoff of its pharmaceutical group was on track for 2013 and would likely be completed by June of that year. The company also unveiled the new name for the company: Mallinckrodt Pharmaceuticals. The name choice… Read More »